KEAP1 and cancer: Taken together, these data have indicated that NRF2 actively participates in the regulation of glutamine metabolism in malignant tumors suggesting that alterations in the KEAP1/NRF2 signaling alone or in combination with concomitant oncogenic activation might uncover specific metabolic vulnerabilities that might be therapeutically targeted to treat otherwise resistant tumors [116].